All the news Showing 10 of 248 articles from: Interferon-free regimensGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Achillion Announces 100% SVR Reported in Janssen’s Phase 2a Trial Evaluating Triple Combination of Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naive HCV Achillion press release / 09 September 2016 European Commission Grants Marketing Authorisation for MSD’s ZEPATIER™ (elbasvir/grazoprevir) for the Treatment of Chronic Hepatitis C Infection MSD press release / 02 August 2016 European Commission Grants Marketing Authorization for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C Gilead press release / 08 July 2016 Sofosbuvir/ledipasvir regimens can cost less per cure than older hepatitis C treatments Liz Highleyman / 20 June 2016 The cost of treating chronic hepatitis C with sofosbuvir/ledipasvir (Harvoni) is lower than the cost of prior interferon-based therapy with first-generation direct-acting antivirals (DAAs), in part because the newer drugs are well ... ABT-493 + ABT-530 cures most hepatitis C patients across genotypes in SURVEYOR studies Liz Highleyman / 03 June 2016 A co-formulation of AbbVie's experimental next-generation direct-acting antiviral agents ABT-493 and ABT-530 was well-tolerated and led to sustained virological response in 97% or more of patients across all hepatitis C virus (HCV) genotypes ... Sofosbuvir/velpatasvir produces high hepatitis C cure rates and subjective improvement in ASTRAL trials Liz Highleyman / 31 May 2016 A co-formulation of Gilead Science's sofosbuvir and its investigational hepatitis C virus (HCV) NS5A inhibitor velpatasvir taken for 12 weeks produced sustained virological response in 95 to 99% of participants across HCV genotypes ... Merck Receives Positive CHMP Opinion for ZEPATIER™ (elbasvir and grazoprevir) in the European Union MSD press release / 30 May 2016 Elbasvir/grazoprevir superior to sofosbuvir and pegylated interferon/ribavirin Michael Carter / 10 May 2016 New research has demonstrated the clear superiority of an oral combination of direct-acting antivirals (DAAs) over a regimen that combines a DAA with pegylated interferon and ribavirin for the treatment of chronic hepatitis ... Adolescents with hepatitis C achieve high cure rates with sofosbuvir/ledipasvir Liz Highleyman / 25 April 2016 Sofosbuvir/ledipasvir (Harvoni) was well tolerated and led to sustained virological response in 97% of adolescents (age 12-17) with chronic hepatitis C, with high cure rates regardless of prior treatment experience or presence ... Novel therapy RG-101 plus antivirals could cure hepatitis C in 4 weeks Liz Highleyman / 20 April 2016 Two injections of RG-101, an experimental drug that targets the micro-RNA miR-122 in liver cells, combined with direct-acting antiviral agents (DAAs) taken for just 4 weeks, led to 12-week post-treatment sustained response in ... ← Prev12345...25Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive